Organisation paid for research Program year 2025 Source: CMS Open Payments

Pharmaceuticals Research Consulting Inc.

Neither a doctor nor a teaching hospital

Research payments

$479,434

15 payments

Through program year 2025, Pharmaceuticals Research Consulting Inc. is reported as receiving $479,434 in research payments, across 15 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$231,285	7
2024	Research	$171,758	5
2023	Research	$76,392	3

Breakdown

Who paid Research payments · program years 2023–2025

AstraZeneca Pharmaceuticals LP $479,434 15 payments

Studies the money was for Research payments · program years 2023–2025

A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma $148,454 3 payments
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma $142,325 3 payments
A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyposis WAYPOINT $105,295 5 payments
a randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with asthma ACADIA $78,249 3 payments
ALTA - Albuterol budesonide Treatment in Acute airway obstruction his is a multi-center randomized double-blind 2-period cross-over study evaluating efficacy and safety of repeated doses of PT027 albuterol budesonide pressurized metered dose inhaler pMDI compared to PT007 albuterol pMDI in participants with asthma and acute airway obstruction induced by 2 mannitol challenges 7 hours apart $5,112 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.